The gut microbiota metabolism of pomegranate or walnut ellagitannins yields two urolithin-metabotypes that correlate with cardiometabolic risk biomarkers: Comparison between normoweight, overweight-obesity and metabolic syndrome


Creative Commons License

Selma M. V., Gonzalez-Sarrias A., Salas-Salvado J., Andres-Lacueva C., Alasalvar C., ÖREM A., ...Daha Fazla

CLINICAL NUTRITION, cilt.37, sa.3, ss.897-905, 2018 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 37 Sayı: 3
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1016/j.clnu.2017.03.012
  • Dergi Adı: CLINICAL NUTRITION
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.897-905
  • Anahtar Kelimeler: Cardiovascular, Metabotype, Ellagic acid, Gut microbiota, Obesity, Polyphenols, ELLAGIC ACID METABOLISM, CARDIOVASCULAR-DISEASE, FOLLOW-UP, CONSUMPTION, GORDONIBACTER, ANTIOXIDANT, VARIABILITY, PHENOTYPES, DAIDZEIN, BLIND
  • Karadeniz Teknik Üniversitesi Adresli: Evet

Özet

Background & aims: Urolithins are microbial metabolites produced after consumption of ellagitannin-containing foods such as pomegranates and walnuts. Parallel to isoflavone-metabolizing phenotypes, ellagitannin-metabolizing phenotypes (urolithin metabotypes A, B and 0; UM-A, UM-B and UM-0, respectively) can vary among individuals depending on their body mass index (BMI), but correlations between urolithin metabotypes (UMs) and cardiometabolic risk (CMR) factors are unexplored. We investigated the association between UMs and CMR factors in individuals with different BMI and health status.